CYT News and Press, Cyteir Therapeutics Inc. From 05/31/22

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentatio...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Cyteir Therapeutics press release (NASDAQ:CYT): Q1 GAAP EPS of -$0.40 misses by $0.01. Ended quarter with approximately $177.4 million in cash with projected cash runway into 2024 to support planned R&D and clinical studies For further details see: Cyteir Therapeutics GAAP EPS of -$...

- Safety and efficacy data expected for second half 2022 for CYT-0851 monotherapy and combination studies - CYT-0851 mechanism of action identified as inhibition of monocarboxylate transporter (MCT) activity; new findings potentially expand future opportunities into new tumor types ...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Andrew Gengos, Chief Business Officer and Judd Englert, MD, PhD, Senior Vice President Clinic...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice Presid...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a virtual R&D Day on April 26, 2022 starting at 8:30 a.m. ET. Cyteir’s management will ...

The following slide deck was published by Cyteir Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Cyteir Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Gainers: Eiger BioPharmaceuticals (EIGR) +36%. Cyteir Therapeutics (CYT) +30%. PAVmed (PAVM) +28%. Cingulate (CING) +26%. Bone Biologics (OTCPK:BBLG) +22%. Losers: Incannex Healthcare Limited (IXHL) -12%. Jounce Therapeutics (JNCE) -9%. Rapid Micro Biosystems (RPID) -...

Cyteir Therapeutics, Inc. (CYT) Q4 2021 Results Conference Call March 16, 2022 04:30 PM ET Company Participants Lisa Hayes - VP, IR and Corporate Communications Dr. Markus Renschler - President and CEO Dave Gaiero - VP, Finance Andrew Gengos - Chief Business Officer Paul Secrist - Chief Scien...